C07K 16/2857
Against nuclear receptors
Official title: {against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor}
C07K16/2857 (Against nuclear receptors) appears on 36 US grants and 76 published applications in this corpus.
Search patents in C07K- Granted patents
- 36
- Published applications
- 76
- Assignees
- 49
- Inventors
- 161
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 1 | 4 |
| 2007 | 1 | 2 |
| 2008 | 1 | 0 |
| 2009 | 3 | 4 |
| 2010 | 1 | 3 |
| 2011 | 0 | 1 |
| 2012 | 1 | 1 |
| 2013 | 0 | 3 |
| 2014 | 0 | 2 |
| 2015 | 0 | 5 |
| 2016 | 3 | 2 |
| 2017 | 2 | 3 |
| 2018 | 0 | 5 |
| 2019 | 3 | 3 |
| 2020 | 1 | 6 |
| 2021 | 2 | 5 |
| 2022 | 6 | 4 |
| 2023 | 1 | 6 |
| 2024 | 1 | 3 |
| 2025 | 4 | 7 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for diabetes treatment and β-cell regeneration19 May 2026US 12,630,638 B2The Regents of the University of California
- Dosing regimes for treatment of synucleinopathies7 Apr 2026US 12,595,295 B2Hoffmann-La Roche Inc.
- Modulators of ROR1-ROR2 binding29 Apr 2025US 12,286,480 B2The Regents of the University of California
- Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)8 Apr 2025US 12,268,741 B2Juno Therapeutics, Inc.
- Fusion constructs and methods of using thereof14 Jan 2025US 12,194,094 B2Precigen, Inc.
- Dosing regimes for treatment of synucleinopathies13 Aug 2026US 2026/0234230 A1F. Hoffmann-La Roche AG
- Neuropilin-1-peptide based antibody, highliting new epitope associated to glycosaminoglycan-modified neuropilin-1 and methods of use thereof6 Aug 2026US 2026/0226176 A1
- Methods and compositions for diabetes treatment and beta-cell regeneration2 Jul 2026US 2026/0184796 A1The Regents of the University of California
- Compositions and methods2 Apr 2026US 2026/0092120 A1Flagship Pioneering Innovations Vii, LLC
- Antibody or antigen-binding fragment thereof15 Jan 2026US 2026/0016477 A1Osaka Prefectural Hospital Organization
Most cited
By later US patents
- Conversion of apoptotic proteins93US 6,994,979 B2The Burnham Institute · 2006
- Anti-human ROR1 antibodies31US 9,316,646 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2016
- Fibronectin binding domains with reduced immunogenicity18US 9,522,951 B2Bristol-Myers Squibb Company · 2016
- Chimeric rabbit/human ROR1 antibodies16US 9,758,586 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2017
- Fibronectin binding domains with reduced immunogenicity15US 9,416,170 B2Bristol-Myers Squibb Company · 2016